Mesothelial cells promote early Ovarian cancer metastasis through fibronectin secretion

Journal of Clinical Investigation

Volumn 124, Issue 10, 2014, Pages 4614-4628

  Kenny, Hilary A ^a   Chiang, Chun Yi ^a   White, Erin A ^a   Schryver, Elizabeth M ^a   Habis, Mohammed ^a   Romero, Iris L ^a   Ladanyi, Andras ^a   Penicka, Carla V ^a   George, Joshy ^b,c   Matlin, Karl ^a   Montag, Anthony ^d   Wroblewski, Kristen ^a   Yamada, S Diane ^a   Mazar, Andrew P ^e   Bowtell, David ^b,c   Lengyel, Ernst ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF CHICAGO   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA5 INTEGRIN ANTIBODY; ANTIMETASTATIC AGENT; BETA1 INTEGRIN; BETA1 INTEGRIN ANTIBODY; BLOCKING ANTIBODY; FIBRONECTIN; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; RAC1 PROTEIN; SMAD PROTEIN; SMAD3 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; INTEGRIN; TGFB1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PREVENTION; CELL ADHESION; CELL CULTURE; CELL INVASION; CELL PROLIFERATION; CELL STIMULATION; CLINICAL EVALUATION; COCULTURE; CONTROLLED STUDY; DRUG POTENTIATION; EARLY CANCER; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MESOTHELIUM CELL; METASTASIS INHIBITION; MURINE MODEL; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; OVARY METASTASIS; PHENOTYPIC VARIATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR INVASION; TUMOR PROMOTION; UPREGULATION; ANIMAL; CYTOLOGY; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; METASTASIS; MOUSE; OVARY TUMOR; PATHOLOGY; SECRETION (PROCESS); TUMOR CELL LINE;

ANIMALS; CELL ADHESION; CELL LINE, TUMOR; COCULTURE TECHNIQUES; EPITHELIAL CELLS; EXTRACELLULAR MATRIX; FEMALE; FIBRONECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRINS; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84907483668     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI74778     Document Type: Article

References (66)

1. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177(3):1053-1064.
2. Mutsaers SE. The mesothelial cell. Int J Biochem Cell Biol. 2004;36(1):9-16.
3. Zhang XY, Pettengell R, Nasiri N, Kalia V, Dalgleish AG, Barton DP. Characteristics and growth patterns of human peritoneal mesothelial cells: Comparison between advanced epithelial ovarian cancer and non-ovarian cancer sources. J Soc Gynecol Investig. 1999;6(6):333-340.
4. Niedbala MJ, Crickard K, Bernacki R. Interactions of human ovarian tumor cells with human mesothelial cells grown on extracellular matrix. Exp Cell Res. 1985;160(2):499-513.
5. Iwanicki M, et al. Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov. 2011;1(7):144-157.
6. Davidowitz RA, et al. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J Clin Invest. 2014;124(6):2611-2625.
7. Heath RM, Jayne DG, O'Leary R, Morrison EE, Guillou PJ. Tumor-induced apoptosis in human mesothelial cells: a mechanism of peritoneal invasion by Fas Ligand/Fas interaction. Br J Cancer. 2004;90(7):1437-1442.
8. Rieppi M, et al. Mesothelial cells induce the motility of human ovarian carcinoma cells. Int J Cancer. 1999;80(2):303-307.
9. Ksiazek K, Mikula-Pietrasik J, Korybalska K, Dworacki G, Jorres A, Witowski J. Senescent peritoneal mesothelial cells promote ovarian cancer cell adhesion: The role of oxidative stress-induced fibronectin. Am J Pathol. 2009;174(4):1230-1240.
10. Hanahan D, Coussens LM. Accessories to the crime: Functions of cell recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309-322.
11. Mueller M, Fusenig N. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004;4(11):839-849.
12. Granot D, Addadi Y, Kalchenko V, Harmelin A, Kunz-Schughart LA, Neeman M. In vivo imaging of the systemic recruitment of fibroblasts to the angiogenic rim of ovarian carcinoma tumors. Cancer Res. 2007;67(19):9180-9189.
13. Schauer IG, Sood AK, Mok S, Liu J. Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia. 2011;13(5):393-405.
14. Nieman KM, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17(11):1498-1503.
15. Nieman KM, Romero IL, Van Houten B, Lengyel E. Adipocyte tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta. 2013;1831(10):1533-1541.
16. Burleson KM, Casey RC, Skubitz KM, Pambuccian SE, Oegema TR, Skubitz AP. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol. 2004;93(1):170-181.
17. Cannistra SA, Ottensmeier C, Niloff J, Orta B, Di Carlo J. Expression and function of β1 and αvβ3 integrins in ovarian cancer. Gynecol Oncol. 1995;58(2):216-225.
18. Bignotti E, et al. Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. Am J Obstet Gynecol. 2007;196(3):245.e1-11.
19. Wilhelm O, Hafter R, Coppenrath E, Pflanz M, Schmitt M, Graeff H. Fibrin-fibronectin compounds in human ovarian tumor ascites and their possible relation to the tumor stroma. Cancer Res. 1988;48(12):3507-3514.
20. Mould AP, et al. Defining the topology of integrin α5β1-fibronectin interactions using inhibitory anti-α5 and anti-β1 monoclonal antibodies. J Biol Chem. 1997;272(28):17283-17292.
21. Desgrosellier JS, Cheresh D. Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9-22.
22. Schwarzbauer JE, Sechler JL. Fibronectin fibrillogenesis: a paradign for fibronectin matrix assembly. Curr Opin Cell Biol. 1999;11(5):622-627.
23. Mitra AK, Sawada K, Tiwari P, Mui K, Gwin K, Lengyel E. Ligand-independent activation of c-Met by fibronectin and α5β1-integrin regulates ovarian cancer invasion and metastasis. Oncogene. 2011;30(13):1566-1576.
24. Zand L, Feng Q, Roskelley CD, Leung P C K, Auersperg N. Differential effects of cellular fibronectin and plasma fibronectin on ovarian cancer cell adhesion, migration, and invasion. Int J Biochem Cell Biol. 2003;39(3-4):178-182.
25. Kenny HA, Krausz T, Yamada SD, Lengyel E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells. Int J Cancer. 2007;121(7):1463-1472.
26. Daya D, McCaughy WT. Pathology of the peritoneum: A review of selected topics. Semin Diagn Pathol. 1991;8(4):277-289.
27. Kenny HA, Nieman KM, Mitra AK, Lengyel E. The first line of intra-abdominal metastatic attack: Breaching the mesothelial cell layer. Cancer Discov. 2011;1(2):100-102.
28. Michaelson JE, Ritzenthaler J, Roman J. Regulation of serum-induced fibronectin expression by protein kinases, cytoskeletal integrity, and CREB. Am J Physiol Lung Cell Mol Physiol. 2002;282(2):L291-L301.
29. Sakai T, et al. Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nat Med. 2001;7(3):324-330.
30. Yang J, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117(7):927-939.
31. Tothill RW, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16):198-208.
32. Sandoval P, et al. Carcinoma-associated fibroblasts derive from mesothelial cells via mesothelial to mesenchymal transition in peritoneal metastasis. J Pathol. 2013;231(4):517-531.
33. Yáñez-Mó M, et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med. 2003;348(5):403-413.
34. Yamamura S, et al. The activated transforming growth factor-β signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. Int J Cancer. 2012;130(1):20-28.
35. Yamamoto H, et al. Seperate roles for H-Ras and Rac in signaling by transforming growth factor (TGF)-β. Eur J Biochem. 1999;264(1):110-119.
36. Tse JC, Kalluri R. Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem. 2007;101(4):816-829.
37. Adib TR, Henderson S, Perrett C, Bourmpoulia D, Lederman J, Boshoff C. Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer. 2004;90(3):686-692.
38. Carbonell WS, De Lay M, Jahangiri A, Park CC, Aghi MK. beta1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer Res. 2013;73(10):3145-3154.
39. Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest. 2008;118(4):1367-1379.
40. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of intiated human prostatic epithelium. Cancer Res. 1999;59(19):5002-5011.
41. Dirat B, et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res. 2011;71(7):2455-2465.
42. Aroeira L, et al. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J Am Soc Nephrol. 2007;18(7):2004-2013.
43. Zavadil J, et al. Genetic programs of epithelial cell plasticity directed by transforming growth factor-β. Proc Natl Acad Sci U S A. 2001;98(12):6686-6691.
44. Han G, Lu SL, He W, Corless CL, Kulesz-Martin M, Wang XJ. Distinct mechanisms of TGF-β1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis. J Clin Invest. 2005;115(7):1714-1723.
45. Holmdahl L. The role of fibrinolysis in adhesion formation. Eur J Surg. 1997;(577):] 24-31.
46. Sengupta S, Nandi S, Hindi ES, Wainwright DA, Han Y, Lesniak MS. Short hairpin RNA-mediated fibronectin knowkdown delays tumor growth in a mouse glioma model. Neoplasia. 2010;12(10):837-847.
47. Franke EE, Von Georgi R, Zygmunt M, Munstedt K. Association between fibronectin expression and prognosis in ovarian carcinoma. Anticancer Res. 2003;25(118):1331-1339.
48. Sawada K, Ohyagi-Hara C, Kimura T, Morishige Ki. Integrin inhibitors as a therapeutic agent for ovarian cancer. J Oncol. 2012;2012:915140.
49. Jahangiri A, Aghi MK, Carbonell WS. beta1 integrin: Critical path to antiangiogenic therapy resistance and beyond. Cancer Res. 2014;74(1):3-7.
50. Roby KF, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000;21(4):585-591.
51. Sawyer JS, et al. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. J Med Chem. 2003;46(19):3953-3956.
52. Gellibert F, et al. Identification of 1, 5-naphthyridine derivatives as a novel series of potent and selective TGF-β type I receptor inhibitors. J Med Chem. 2004;47(18):4494-4506.
53. Ye X, Wang Y, Rattner A, Nathans J. Genetic mosaic analysis reveals a major role for frizzled 4 and frizzled 8 in controlling ureteric growth in the developing kidney. Development. 2011;138(6):1161-1172.
54. George J, et al. Functional inhibition of Ras by S-trans, trans-farnesyl thiosalicylic acid attenuates atherosclerosis in apolipoprotein E knockout mice. Circulation. 2002;105(20):2416-2422.
55. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci U S A. 2004;101(20):7618-7623.
56. Tsang ML, et al. Characterization of recombinant soluble human transforming growth factor-β receptor type II (rhTGF-β sRII). Cytokine. 1995;7(5):389-397.
57. Sawada K, et al. C-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 2007;67(4):1670-1680.
58. Kenny HA, et al. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res. 2011;17(3):459-471.
59. Abberton KM, et al. Myogel, a novel, basement membrane-rich, extracellular matrix derived from skeletal muscle, is highly adipogenic in vivo and in vitro. Cells Tissue Organs. 2008;188(4):347-358.
60. Gospodarowicz D, Cheng J, Lui GM, Baird A, Böhlent P. Isolatin of brain fibroblast growth factor by heparin-sepharose affinity chromatography: I dentitiy with pituitary fibroblast growth factor. Proc Natl Acad Sci U S A. 1984;81(22):6963-6967.
61. Pfaffl M. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):2002-2007.
62. McKeown-Longo PJ, Mosher D. Binding of plasma fibronectin to cell layers of human skin fibroblasts. J Cell Biol. 1983;97(2):466-472.
63. Hapke S, et al. β3 A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter. Mol Cell Biol. 2001;21(6):2118-2132.
64. Brunner M, et al. Osteoblast mineralization requires β1 integrin/ICAP-1-dependent fibronectin deposition. J Cell Biol. 2011;194(2):307-322.
65. Indraccolo S, et al. Gene transfer in ovarian cancer cells: A comparison between retroviral and lentiviral vectors. Cancer Res. 2002;62(21):6099-6107.
66. Bhaskar V, et al. A function blocking anti-mouse integrin α5β1 antibody inhibits angiogenesis and impedes tumor growth in vivo. J Transl Med. 2007;5(61):1-11.